L-tryptophan and eosinophilia-myalgia syndrome in New Mexico
| Autor: | Millicent Eidson, R. M. Philen, Ron Voorhees, C. M. Sewell, EdwinM. Kilbourne |
|---|---|
| Rok vydání: | 1990 |
| Předmět: |
Adult
myalgia medicine.medical_specialty New Mexico Pain Disease Outbreaks Leukocyte Count Eosinophilia–myalgia syndrome Muscular Diseases Internal medicine White blood cell Eosinophilia Product Surveillance Postmarketing medicine Humans Aged Retrospective Studies United States Food and Drug Administration business.industry Public health Confounding Tryptophan Retrospective cohort study Syndrome General Medicine Middle Aged Legislation Drug medicine.disease United States medicine.anatomical_structure Space-Time Clustering Drug Evaluation Regression Analysis Female medicine.symptom business |
| Zdroj: | The Lancet. 335:645-648 |
| ISSN: | 0140-6736 |
| Popis: | On Oct 30, 1989, the New Mexico Health and Environment Department learned of 3 patients with eosinophilia and severe myalgia who had been taking L-tryptophan. Further review of these and similar cases led to the initial recognition of the eosinophilia-myalgia syndrome (EMS) epidemic. To elucidate the apparent association between L-tryptophan-containing products (LTCPs) and EMS a case-control study was done. The case definition was unexplained peripheral eosinophilia (2000/microliters or more) and incapacitating myalgia. Cases were found through review of white blood cell counts from May 1 to Oct 31, 1989, in nine medical laboratories in New Mexico. 11 cases and 22 matched controls were interviewed for information on symptoms and other clinical findings, on the use of LTCPs, and on potential confounding factors. All 11 cases (100%) used LTCPs compared with only 2 controls. These findings led to a ban on the sale of LTCPs in New Mexico, followed by a nationwide recall of such preparations in the United States. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|